Core Viewpoint - The company has entered into an asset purchase agreement to acquire assets related to Alexza Pharmaceuticals for a total consideration of $15 million, which aligns with its strategy to expand its innovative drug delivery technology portfolio and global outreach [1][2]. Group 1: Acquisition Details - The buyer, Nova Pneuma Incorporated, a wholly-owned subsidiary of the company, will acquire all assets related to Alexza's business, including properties, equipment, materials, patents, and other intellectual property [1]. - The total purchase price for the assets is set at $15 million [1]. Group 2: Strategic Alignment - The acquisition supports the company's strategy to expand its product portfolio through the Staccato® platform, which has a wide range of therapeutic potential [2]. - The assets acquired are expected to complement the existing product pipeline and create synergies [2]. - The agreement with UCB, a leading biopharmaceutical company in the epilepsy treatment field, marks a significant milestone in the company's global expansion strategy [2].
李氏大药厂(00950)：附属拟1500万美元收购Alexza Pharmaceuticals...